The Irvine, Calif.-based firm finished 2012 strong, reporting profits of $15.0 million, or 26¢ per share, on sales of $132.2 million for the 3 months ended Dec. 31, 2012. That represents an 18% sales bump from the same quarter last year.
For the full year, Masimo reported profits of $62.3 million, or $1.07 per share, on sales of $593.2 million, for a bottom-line slip of 2% compared with 2011.
Adjusted to exclude 1-time items, Q4 earnings per share were 29¢ apiece, a penny ahead of Wall Street analysts’ expectations. Full-year adjsuted EPS were $1.16, in line with expectations on The Street.
"We’ve entered 2013 fully focused on advancing our mission, strategy, and 2013 objectives, which is to continue to grow our core SET pulse oximetry business by increasing our presence in critical care and the general ward, while leveraging our breakthrough rainbow Pulse CO-oximetry platform to pursue new opportunities in and beyond the hospital setting," CEO Joe Kiani said in a company statement.
For 2013, Masimo said it expects revenues to reach $548 million.